Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.61)
# 3,917
Out of 4,931 analysts
55
Total ratings
28.57%
Success rate
-29.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $5.13 | +114.63% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $18.45 | +68.02% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.21 | +1,466.88% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $4.14 | +407.86% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $2.77 | +80.83% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.25 | +1,180.00% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $5.90 | +1,933.90% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $8.03 | +211.33% | 2 | May 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $6.80 | +2,841.18% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.45 | +384.43% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.49 | +573.40% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $10.57 | +467.64% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.68 | +786.66% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $5.33 | +87.62% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.90 | +26,448.67% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $6.98 | +2,507.45% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.23 | +34,472.17% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.44 | +721.36% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.00 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.98 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.40 | +150.00% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $6.13 | +242.86% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $6.90 | +152,175.43% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.57 | +1,339.69% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $22.00 | +1,263.64% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $559.84 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $77.96 | +14.16% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $125.58 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $0.56 | +179,885.28% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.44 | +23,314.63% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.26 | +452.15% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.13
Upside: +114.63%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $18.45
Upside: +68.02%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.21
Upside: +1,466.88%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $4.14
Upside: +407.86%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $2.77
Upside: +80.83%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.25
Upside: +1,180.00%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $5.90
Upside: +1,933.90%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $8.03
Upside: +211.33%
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $6.80
Upside: +2,841.18%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.45
Upside: +384.43%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.49
Upside: +573.40%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $10.57
Upside: +467.64%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.68
Upside: +786.66%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $5.33
Upside: +87.62%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.90
Upside: +26,448.67%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $6.98
Upside: +2,507.45%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.23
Upside: +34,472.17%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $2.44
Upside: +721.36%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.00
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.98
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.40
Upside: +150.00%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $6.13
Upside: +242.86%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $6.90
Upside: +152,175.43%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.57
Upside: +1,339.69%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $22.00
Upside: +1,263.64%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $559.84
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $77.96
Upside: +14.16%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $125.58
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $0.56
Upside: +179,885.28%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.44
Upside: +23,314.63%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.26
Upside: +452.15%